You are here

Dupixent

Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib

Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib

Endpoints

atopic dermatitis

clinical trials

Flag link:

Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp

Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp

Fierce Pharma

Flag link:

Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data

Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data

Fierce Pharma

eosinophilic esophagitis

Flag link:

Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

BioSpace

clinical trials

Flag link:

Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis

Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis

Pharmaceutical Business Review

eosinophilic esophagitis

breakthrough status

Flag link:

Can Sanofi's top drug carry it through a pandemic?

Can Sanofi's top drug carry it through a pandemic?

BioPharma Dive

Flag link:

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Endpoints

Flag link:

LEO eyeing 2021 US launch for eczema drug tralokinumab

LEO eyeing 2021 US launch for eczema drug tralokinumab

Pharmaforum

Flag link:

Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug

Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug

Yahoo/SmarterAnalyst

atopic dermatitis

Flag link:

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema

Endpoints

clinical trials

Flag link:

Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids

Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids

BioSpace

atopic dermatitis

Flag link:

Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split

Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split

Endpoints

esosinophilic esophagitis

clinical trials

Flag link:

Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?

Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?

Motley Fool

Flag link:

Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout

Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout

Fierce Biotech

atopic dermatitis

Flag link:

Sanofi and Regeneron's Dupixent shows more encouraging results

Sanofi and Regeneron's Dupixent shows more encouraging results

Reuters

atopic dermatitis

clinical trials

Flag link:

Will Eczema Drug Dupixent Transform Sanofi?

Will Eczema Drug Dupixent Transform Sanofi?

Motley Fool

Flag link:

Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema

Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema

Pharmaforum

atopic dermatitis

Flag link:

Upcoming events – Pfizer's abrocitinib and Myovant's relugolix

Upcoming events – Pfizer's abrocitinib and Myovant's relugolix

EP Vantage

uterine fibroids

Flag link:

Leo's Dupixent rival hits all endpoints in pivotal program

Leo's Dupixent rival hits all endpoints in pivotal program

Fierce Biotech

atopic dermatitis

Flag link:

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

Stat

Flag link:

Pages